- Home
- MAX vs RCKT Comparison
MAX vs RCKT Comparison
Compare MAX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | RCKT |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.1M | 394.2M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MAX | RCKT |
|---|---|---|
| Price | $9.74 | $2.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $15.43 | $8.85 |
| AVG Volume (30 Days) | 676.7K | ★ 1.6M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.81 | ★ 26.37 |
| EPS | ★ 0.86 | 0.66 |
| Revenue | ★ $1,113,600,000.00 | N/A |
| Revenue This Year | $17.31 | N/A |
| Revenue Next Year | $8.70 | $915.60 |
| P/E Ratio | $10.92 | ★ $3.91 |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $2.51 |
| 52 Week High | $14.70 | $5.45 |
Technical Indicators
Market Signals| Indicator | MAX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 28.87 |
| Support Level | $9.41 | N/A |
| Resistance Level | $10.26 | $3.67 |
| Average True Range (ATR) | 0.55 | 0.21 |
| MACD | -0.06 | -0.09 |
| Stochastic Oscillator | 23.19 | 7.23 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.